About Cyclerion
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company applying neurological insights to discover, develop, and commercialize innovative medicines for people with serious diseases of the central nervous system (CNS). Lead programs include CY6463, a pioneering CNS-penetrant sGC stimulator in clinical development for Alzheimer's Disease with Vascular pathology (ADv), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS), and Cognitive Impairment Associated with Schizophrenia (CIAS). Cyclerion is also advancing CY3018, a next-generation sGC stimulator.
|
|
|
1-10 employees
View all Cyclerion employees
|
|
Biotechnology
|
|
Cambridge, MA 02142, US
|
|
2019
|
Cyclerion Alternatives
Frequently Asked Questions about Cyclerion
Peter Hecht is the CEO of Cyclerion. To contact Peter Hecht email at [email protected].
The decision makers in Cyclerion are Cesar Ardon, Chad Glasser, Fabien Boulineau, etc. Click to Find Cyclerion decision makers emails.
Cyclerion Staff Directory
Search Cyclerion Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
